Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 1/20 | 0.42 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.37 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13641054 | 0.88 | ALDH1A1 (0.42) | TNKSTNKS2OPRM1OPRL1AVPR1A | |
| SCHEMBL12084593 | 0.87 | TNKS (0.44) | TNKSTNKS2OPRM1OPRL1OPRK1 | |
| SCHEMBL13641003 | 0.84 | MEN1 (0.40) | TNKSTNKS2OPRM1OPRL1OPRK1 | |
| SCHEMBL13640817 | 0.84 | OPRM1 (0.44) | TNKSTNKS2OPRM1OPRL1OPRK1 | |
| SCHEMBL14426246 | 0.83 | TNKS (0.40) | TNKSTNKS2OPRM1OPRL1OPRK1 | |
| SCHEMBL14426243 | 0.81 | TNKS (0.40) | TNKSTNKS2OPRM1OPRL1AVPR1A | |
| SCHEMBL13880030 | 0.80 | OPRM1 (0.44) | TNKSTNKS2OPRM1OPRL1AVPR1A | |
| SCHEMBL12084508 | 0.80 | OPRL1 (0.48) | TNKSTNKS2OPRM1OPRL1OPRK1 | |
| SCHEMBL14426244 | 0.80 | TNKS (0.41) | TNKSTNKS2OPRM1OPRL1OPRK1 | |
| SCHEMBL13644096 | 0.79 | TNKS (0.44) | TNKSTNKS2OPRM1OPRL1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497295-B2 | Spiroindoline modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-30 | — | — | US | disclosed |
| US-20120283243-A1 | Spiroindoline Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283243-A1 | Spiroindoline Modulators of Muscarinic Receptors | CHRM3, CHRM2, CHRM5 | TNKS 3506/4885TNKS2 3489/4885OPRM1 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.